Newlink Genetics reported $86.76M in Cash and Equivalent for its first fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Cash And Equivalent Change
Agenus AGEN:US $ 247.71M 44.22M
Bristol Myers Squibb BMY:US $ 12369M 1610M
Capricor Therapeutics CAPR:US $ 58.33M 23.45M
Celldex Therapeutics CLDX:US $ 25.29M 13.85M
Eli Lilly And LLY:US $ 2459.2M 1359.3M
Idera Pharmaceuticals IDRA:US $ 27.99M 4.55M
Intrexon XON:US $ 40.32M 2.6M
Merk MRK:US $ 8556M 460M
Nektar Therapeutics NKTR:US $ 67.99M 42.78M
Newlink Genetics NLNK:US $ 86.76M 8.05M
Pfizer PFE:US $ 2470M 526M
Prothena PRTA:US $ 542.99M 36.1M
Sarepta Therapeutics SRPT:US $ 1233.88M 881.99M
Vascular Biogenics VBLT:US 13.25M 8.73M
YTE INCY:US $ 2256.76M 199.32M